Mettler-Toledo delivered solid Q3 2025 results, underscoring durable demand for precision instrumentation across life sciences, analytical chemistry and related laboratories. Revenue of USD 1.030 billion rose 7.87% year over year and 4.73% quarter over quarter, supported by a favorable mix and ongoing investment in measurement technologies. Gross profit reached USD 609.46 million with a gross margin of 59.19% (reported 0.5919), while EBITDA stood at USD 322.64 million and operating income was USD 309.92 million, translating to operating margins near 30.10%. Net income was USD 217.49 million and diluted EPS was USD 10.57, reflecting disciplined cost management and leverage in the core growth engines.
The company demonstrated meaningful profitability and cash flow strength. Net margin was 21.12% and the net income grew 2.83% YoY (7.48% QoQ), while free cash flow per share was USD 13.29 and operating cash flow per share USD 14.47, highlighting robust cash generation relative to earnings. The balance sheet shows conservative leverage with a debt ratio of ~0.628 and a solid interest coverage of ~17.5x, supporting ongoing investment in product development, capacity expansion and service capabilities. The quarterβs performance reinforces MTβs premium positioning in a high-growth, regulated equipment category with strong installed-base resilience and aftermarket services potential.
Despite the strength, valuation remains elevated relative to broader industrial peers, consistent with MTβs market leadership, branded product suite and pricing power. Investors should monitor capital expenditure cycles in life sciences, currency dynamics, and any shifts in end-market demand that could influence instrument orders and aftermarket services growth.